Our study revealed that SGLT-2 inhibitors decrease the risk of cardiovascular and renal events in type 2 DM patients with CKD, which is compatible with RCTs of CKD patients [11, 12]. This evidence concerns the gene SLC5A2 and chronic kidney disease.